Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.81 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20165463 | 1.00 | ESR1 (0.81) | ESR1ESR2AGTR2 | |
| SCHEMBL20179658 | 0.94 | ESR1 (0.72) | ESR1ESR2 | |
| SCHEMBL20179741 | 0.94 | ESR1 (0.71) | ESR1ESR2 | |
| SCHEMBL29756840 | 0.93 | ESR1 (0.69) | ESR1ESR2 | |
| SCHEMBL20165503 | 0.93 | ESR1 (0.69) | ESR1ESR2 | |
| SCHEMBL20165501 | 0.93 | ESR1 (0.69) | ESR1ESR2 | |
| SCHEMBL29756837 | 0.91 | ESR1 (0.80) | ESR1 | |
| SCHEMBL20165199 | 0.91 | ESR1 (0.80) | ESR1 | |
| Amcenestrant SCHEMBL23162989 | 0.89 | ESR1 (1.00) | ESR1ESR2AGTR2 | |
| Amcenestrant SCHEMBL19131426 | 0.89 | ESR1 (1.00) | ESR1ESR2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109963848-B | Substituted N- (3-fluoropropyl) -pyrrolidine compounds, preparation thereof and therapeutic use thereof | 赛诺菲 | 2022-07-05 | — | — | CN | disclosed |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | ESR1, CYP19A1, GPER1 | ESR1 1/4885ESR2 4/4885AGTR2 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.